Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

BACKGROUND: The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. METHODS: Box and Whisker plot analysis, Scatter plo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Yamada, Taketo, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, Morimoto, Chikao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989014/
https://www.ncbi.nlm.nih.gov/pubmed/33757558
http://dx.doi.org/10.1186/s40364-021-00273-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989014/
https://www.ncbi.nlm.nih.gov/pubmed/33757558
http://dx.doi.org/10.1186/s40364-021-00273-0

Ejemplares similares